Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery s…
Insiders
Transactions
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$3,013,468
i
Common shares
10% Holder
|
12/24/24 |
C
|
250,000 x $10.00 = $2,500,000.00 |
Footnotes
#1 Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00.
#2 Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein
|
|||
|
$3,013,468
i
Common shares
10% Holder
|
12/24/24 |
C
|
250,000 x $10.00 = $2,500,000.00 |
Footnotes
#1 Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00.
#2 Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein
|
|||
|
$319,334
d
cs
10% Holder
|
10/22/24 |
M
|
16,666 x $6.00 = $99,996.00 |
Footnotes
|
|||
|
$2,732,586
i
Common Shares
10% Holder
|
04/18/24 |
C
|
991,615 x $0 = $0 |
Footnotes
#1 991,615 Common shares are acquired via conversion of 1,065 F-2 preferred shares and 3,010 F-3 preferred shares.
#2 Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.
#3 619,946 common shares acquired via exercise of pre-funded warrants at $0.01.
|
|||
|
$2,732,586
i
Common Shares
10% Holder
|
04/18/24 |
X
|
619,946 x $6,199.46 = $3,843,330,429.16 |
Footnotes
#1 991,615 Common shares are acquired via conversion of 1,065 F-2 preferred shares and 3,010 F-3 preferred shares.
#2 Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.
#3 619,946 common shares acquired via exercise of pre-funded warrants at $0.01.
|
|||
Get PRO Today
With PRO you will unlock 17 more insider transactions for Delcath Systems, Inc.
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Aharon Gil Director
- Czerepak Elizabeth EVP & Chief Financial Officer
- Dias Anthony VP FINANCE
- Hoffman David L. GEN'L COUNSEL, CCO & SECY
- John Johnny SVP CLINICAL DEV & MED AFFAIRS
- Martell Bridget A Director
- Michel Gerard J CHIEF EXECUTIVE OFFICER
- Muir Kevin GM INTERVENTIONAL ONCOLOGY
- Pennell Sandra SVP OF FINANCE, PFO AND PAO
- Purpura John CHIEF OPERATING OFFICER
- Rook Martha S. CHIEF OPERATING OFFICER
- Salamon Steven A J Director
- Stoll Roger G Phd Director
- Sylvester John Richard Director
- Vukovic Vojo CHIEF MEDICAL OFFICER
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Aharon Gil Director
- Czerepak Elizabeth EVP & Chief Financial Officer
- Dias Anthony VP FINANCE
- Hoffman David L. GEN'L COUNSEL, CCO & SECY
- John Johnny SVP CLINICAL DEV & MED AFFAIRS
- Martell Bridget A Director
- Michel Gerard J CHIEF EXECUTIVE OFFICER
- Muir Kevin GM INTERVENTIONAL ONCOLOGY
- Pennell Sandra SVP OF FINANCE, PFO AND PAO
- Purpura John CHIEF OPERATING OFFICER
- Rook Martha S. CHIEF OPERATING OFFICER
- Salamon Steven A J Director
- Stoll Roger G Phd Director
- Sylvester John Richard Director
- Vukovic Vojo CHIEF MEDICAL OFFICER